An Integrated Analysis Of Gene Expression And Chromosome Copy Number In Malignant Mesothelioma
Funder
National Health and Medical Research Council
Funding Amount
$421,697.00
Summary
Mesothelioma is an aggressive, asbestos related cancer which causes more than 20,000 deaths worldwide per annum. Mesothelioma is characterised by a long latency between exposure to asbestos and development of the disease, estimated to be between 20 and 40 years. As such, the peak number of cases of mesothelioma is not expected in Australia until 2010, as asbestos use reached its peak in the 1970-80's. In 2010, deaths from mesothelioma will be more common than ovarian cancer and melanoma. This st ....Mesothelioma is an aggressive, asbestos related cancer which causes more than 20,000 deaths worldwide per annum. Mesothelioma is characterised by a long latency between exposure to asbestos and development of the disease, estimated to be between 20 and 40 years. As such, the peak number of cases of mesothelioma is not expected in Australia until 2010, as asbestos use reached its peak in the 1970-80's. In 2010, deaths from mesothelioma will be more common than ovarian cancer and melanoma. This study aims to explore the molecular defects that are involved in initiation and progression of mesothelioma. Using array comparative genomic hybridisation, a technique which allows comparison of the DNA of normal cells with that of cancer cells, we will classify chromosomal changes in the cancer cell and identify candidate genes which are involved in mesothelioma development.Read moreRead less
Boosting Effectiveness Of New Vaccines For Dengue ,HFMD And Influenza By Targeting Vaccine Antigens To Clec9A On Dendritic Cells.
Funder
National Health and Medical Research Council
Funding Amount
$396,332.00
Summary
Australian and Singapore laboratories will collaborate to develop improved vaccines against virus diseases, particularly Dengue, Hand Foot and Mouth Disease and Influenza. A novel technology will be used, the targeting of vaccines to a receptor on the surface of the dendritic cells that control immune responses. This will be used to boost responses to a series of vaccine candidates that are otherwise insufficiently immunogenic.